---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124655"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:46:55.705736+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Atossa Therapeutics reports Q3 2024 results, highlights positive Phase 2 data for (Z)-endoxifen

## Summary
- Announced positive topline from KARISMA-Endoxifen Phase 2: MBD reductions of 19.3% (1 mg) and 26.5% (2 mg) vs placebo.
- Preliminary I-SPY 2 EOP analysis: 95% (19/20) of patients met primary endpoint with >75% treatment completion.
- First patient dosed in combination trial of (Z)-endoxifen with abemaciclib (VERZENIO) in ER+/HER2- breast cancer.
- Ended Q3 2024 with $74.8 million cash and equivalents, no debt.
- Received new U.S. Patent No. 12,071,391 covering (Z)-endoxifen compositions.

## SEC filing metadata
- accession: 0000950170-24-124655
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000095017024124655/0000950170-24-124655-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000095017024124655/atos-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124655
- JSON: https://secwatch.observer/filing/0000950170-24-124655.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124655.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.